Mark Czekaj

Optimization of the β-Aminoester class of factor Xa inhibitors. part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity

Kevin R. Guertin, Charles J. Gardner, Scott I. Klein et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas et al. · The Lancet Diabetes & Endocrinology · 2023 · 40 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +11

Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

Scott I. Klein, Mark Czekaj, Charles J. Gardner et al. · Journal of Medicinal Chemistry · 1998 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine E. Jones et al. · The Lancet Child & Adolescent Health · 2024 · 38 citations · Full text

Life Sciences, Immunology, Pediatrics +15

Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase

Corey R. Hopkins, Mark Czekaj, Steven S. Kaye et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 35 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16